Why Ascendo Biotechnology
First-in-Class Mechanism of Action
ASD141 is a first-in-class clinical-stage therapeutic targeting the TLT-1/CD11b checkpoint axis — a validated and commercially unexplored target in innate immune oncology.
Addresses the Root of Resistance
Rather than targeting downstream adaptive immune signals, we intervene upstream at the innate immune level — the stage where most current therapies fail to act.
Designed for Combination
Preclinical data confirm synergistic anti-tumor activity when ASD141 is combined with anti-PD-1 or anti-CTLA-4, without additive toxicity — making it an ideal add-on for pharma partners with existing checkpoint programs.
Platform with Dual Indication Potential
The same TLT-1/CD11b biology that drives tumor immune evasion also governs myeloid dysregulation in autoimmune disease — giving Ascendo a pipeline spanning two commercially distinct markets from a single scientific platform.
Near-Term Value Catalysts
Ascendo is approaching multiple de-risking milestones that create near-term partnership and investment opportunities.
ASD141’s Phase I readout in 2026 will provide the first clinical validation of our TLT-1/CD11b mechanism — a pivotal inflection point for licensing and co-development discussions.
In 2027, Phase II initiation and ASD001’s IND submission will expand our clinical footprint across both oncology and autoimmune indications, positioning Ascendo as a multi-asset platform partner.
Structured for Flexible Partnerships
